End of dose interval (EDI) symptoms in patients undergoing treatment with natalizumab

por Magro, Giuseppe, De Martino, Antonio, Tosto, Federico, Santangelo, Domenico, Manzo, Lucia, Bruno, Pietro, Pascarella, Angelo, Pasquale, Marilisa, Barone, Stefania, Gambardella, Antonio, Valentino, Paola
Publicado 2021

Myositis associated to COVID-19 mimics an acute exacerbation in myasthenia gravis patient

por De Martino, Antonio, Barone, Stefania, Santangelo, Domenico, Magro, Giuseppe, Tosto, Federico, Pascarella, Angelo, Manzo, Lucia, Bruno, Pietro, Pasquale, Marilisa, Valentino, Paola, Gambardella, Antonio
Publicado 2021

Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic

por Magro, Giuseppe, Barone, Stefania, Tosto, Federico, De Martino, Antonio, Santange lo, Domenico, Manzo, Lucia, Pascarella, Angelo, Bruno, Pietro, Pasquale, Marilisa, Gambardella, Antonio, Valentino, Paola
Publicado 2022